Association of Structural Forms of 17q21.31 with the Risk of Progressive Supranuclear Palsy and MAPT Sub-haplotypes

Hui Wang,Timothy S Chang,Beth A Dombroski,Po-Liang Cheng,Ya-Qin Si,Albert Tucci,Vishakha Patil,Leopoldo Valiente-Banuet,Kurt Farrell,Catriona Mclean,Laura Molina-Porcel,Rajput Alex,Peter Paul De Deyn,Nathalie Le Bastard,Marla Gearing,Laura Donker Kaat,John C Van Swieten,Elise Dopper,Bernardino F Ghetti,Kathy L Newell,Claire Troakes,Justo G de Yébenes,Alberto Rábano-Gutierrez,Tina Meller,Wolfgang H Oertel,Gesine Respondek,Maria Stamelou,Thomas Arzberger,Sigrun Roeber,Ulrich Müller,Franziska Hopfner,Pau Pastor,Alexis Brice,Alexandra Durr,Isabelle Le Ber,Thomas G Beach,Geidy E Serrano,Lili-Naz Hazrati,Irene Litvan,Rosa Rademakers,Owen A Ross,Douglas Galasko,Adam L Boxer,Bruce L Miller,Willian W Seeley,Vivianna M Van Deerlin,Edward B Lee,Charles L White 3rd,Huw R Morris,Rohan de Silva,John F Crary,Alison M Goate,Jeffrey S Friedman,Yuk Yee Leung,Giovanni Coppola,Adam C Naj,Li-San Wang,PSP genetics study group,Dennis W Dickson,Günter U Höglinger,Jung-Ying Tzeng,Daniel H Geschwind,Gerard D Schellenberg,Wan-Ping Lee

DOI: https://doi.org/10.1101/2024.02.26.24303379

2024-02-28

MedRxiv

Abstract:Importance: The chromosome 17q21.31 region, containing a 900 Kb inversion that defines H1 and H2 haplotypes, represents the strongest genetic risk locus in progressive supranuclear palsy (PSP). In addition to H1 and H2, various structural forms of 17q21.31, characterized by the copy number of α, β, and γ duplications, have been identified. However, the specific effect of each structural form on the risk of PSP has never been evaluated in a large cohort study. Objective: To assess the association of different structural forms of 17q.21.31, defined by the copy numbers of α, β, and γ duplications, with the risk of PSP and MAPT sub-haplotypes. Design setting and participants: Utilizing whole genome sequencing data of 1,684 (1,386 autopsy confirmed) individuals with PSP and 2,392 control subjects, a case-control study was conducted to investigate the association of copy numbers of α, β, and γ duplications and structural forms of 17q21.31 with the risk of PSP. All study subjects were selected from the Alzheimer's Disease Sequencing Project (ADSP) Umbrella NG00067.v7. Data were analyzed between March 2022 and November 2023. Main outcomes and measures: The main outcomes were the risk (odds ratios [ORs]) for PSP with 95% CIs. Risks for PSP were evaluated by logistic regression models. Results: The copy numbers of α and β were associated with the risk of PSP only due to their correlation with H1 and H2, while the copy number of γ was independently associated with the increased risk of PSP. Each additional duplication of γ was associated with 1.10 (95% CI, 1.04-1.17; P = 0.0018) fold of increased risk of PSP when conditioning H1 and H2. For the H1 haplotype, addition γ duplications displayed a higher odds ratio for PSP: the odds ratio increases from 1.21 (95%CI 1.10-1.33, P = 5.47 × 10-5) for H1β1γ1 to 1.29 (95%CI 1.16-1.43, P = 1.35 × 10-6) for H1β1γ2, 1.45 (95%CI 1.27-1.65, P = 3.94 × 10-8) for H1β1γ3, and 1.57 (95%CI 1.10-2.26, P = 1.35 × 10-2) for H1β1γ4. Moreover, H1β1γ3 is in linkage disequilibrium with H1c (R2 = 0.31), a widely recognized MAPT sub-haplotype associated with increased risk of PSP. The proportion of MAPT sub-haplotypes associated with increased risk of PSP (i.e., H1c, H1d, H1g, H1o, and H1h) increased from 34% in H1β1γ1 to 77% in H1β1γ4. Conclusions and relevance: This study revealed that the copy number of γ was associated with the risk of PSP independently from H1 and H2. The H1 haplotype with more γ duplications showed a higher odds ratio for PSP and were associated with MAPT sub-haplotypes with increased risk of PSP. These findings expand our understanding of how the complex structure at 17q21.31 affect the risk of PSP.